Feza Kirbiyik

Dr. Feza Kirbiyik

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in Nutrition
Verified
Journal Article
Open access
ÖBÖmer Faruk Beşer
Ömer Faruk Beşer
FCFugen Cullu Cokugras
Fugen Cullu Cokugras
TETulay Erkan
Tulay Erkan
TKTufan Kutlu
Tufan Kutlu
RYRasit V. Yagci
Rasit V. Yagci
FKFeza Kirbiyik
Feza Kirbiyik
Many screening methods, such as the Screening Tool Risk on Nutritional Status and Growth (STRONGkids) and the Pediatric Yorkhill Malnutrition Score (PYMS), have been developed to detect malnutrition in pediatric patients. We aimed to explore the prevalence of malnutrition risk in hospitalized children via symptoms and identification of contributing factors, and to examine the efficacy of malnutrition screening tools for hospitalized children. STRONGkids and PYMS were applied to 1513 inpatients at 37 hospitals in 26 cities from different regions of Turkey. Physical measurements were collected at hospital admission and at discharge. z-Scores of height-for-age, weight-for-age, weight-for-height, and body mass index-for-age were calculated. Overall, 1513 patients were included in the study. A body mass index standard deviation score of less than -2 was present in 9.5% of the study population at hospital admission, whereas 11.2% of the participants had a weight-for-length/height score of less than -2 at hospital admission. According to STRONGkids results, the proportion of the patients with an underlying chronic disease was higher for the patients at high risk of malnutrition than for the patients at medium or low risk (91% compared with 47% or 45%, respectively). PYMS results indicated that patients at high risk of malnutrition have more chronic diseases (75%) than the patients at medium or low risk of malnutrition (55% and 44%, respectively). Use of anthropometric measurements in addition to screening tools to identify hospital malnutrition (such as PYMS, STRONGkids) will prevent some nutritional risk patients from being overlooked.

1 October 2018 in Clinical Nutrition ESPEN
Verified
Journal Article
Open access
FKFeza Kirbiyik
Feza Kirbiyik
EOEmre Ozkan
Emre Ozkan
Despite the identification of malnutrition and administration of nutrition therapy being increasingly recognised as integral to the treatment of cancer patients, this is not always translated into routine clinical practice. The aim of this study was to determine medical oncologists' awareness of, and ability to assess, nutritional status and when to initiate nutrition therapy, to identify their educational status concerning clinical nutrition and their perceived barriers to the routine use of nutrition therapy in their patients through a survey study. 155 medical oncologists were invited to complete a digital questionnaire. The questionnaire included information regarding the participants demographic and professional information, clinical nutrition education status, attitudes towards malnutrition and nutrition therapy, and barriers to using nutrition therapy. The questionnaire also included two case scenarios designed to assess ability to diagnose malnutrition/assess nutritional status and identify when nutrition therapy might be indicated. Of 109 medical oncologists who agreed to participate, 43.1% declared that they received clinical nutrition education and 33.9% declared that they followed the oncology sections in the European Society of Clinical Nutrition and Metabolism (ESPEN) Guidelines. The medical oncologists were divided into two groups according to their knowledge score (31 medical oncologists with a knowledge score of <3 and 78 medical oncologists with a knowledge score of ≥3). The rate of having nutrition education was significantly higher in those with a higher knowledge score (≥3) and the rate of medical oncologists having this education during medical and/or oncology education was also significantly higher. The rate of medical oncologists following the oncology sections in the ESPEN guidelines was higher in those with higher knowledge score. Our results emphasize the association between clinical nutrition education and higher knowledge scores in medical oncologists, but reveal a mis-match between knowledge and awareness and what happens in clinical practice. Nutrition therapy might be used more frequently in routine practice when medical oncologists' lack of knowledge is resolved.

1 June 2020 in ClinicoEconomics and Outcomes Research
Verified
Journal Article
Open access
PDF file
MBMehmet Berktas
Mehmet Berktas
FKFeza Kirbiyik
Feza Kirbiyik
EAElif Aribal
Elif Aribal
AAAnil Aksit
Anil Aksit
DADerya Ufuk Altintas
Derya Ufuk Altintas
Purpose: Cow’s milk protein allergy (CMPA) is one of the most common food allergies in early childhood. We aimed to evaluate clinical and economic outcomes of the amino-acid formula (AAF) and extensively hydrolyzed formula (eHF) based treatment of CMPA by using data available from Turkey and otherwise from literature. Materials and Methods: A theoretical model was developed to evaluate AAF and eHF for CMPA treatment in terms of the number of children tolerating formula or experiencing an allergic reaction or withdrawing formula due to taste or other palatability features and CMPA related direct medical costs from the payer perspective. Results: We estimated that 13,000 children are diagnosed with CMPA in 1 year in Turkey. For the children receiving AAF, it is estimated that 83.7% tolerate AAF until the 24th month, and the total cost for the children tolerating AAF is estimated at 20.6 million€. The average cost per child tolerating AAF until the 24th month is estimated at 1895€. On the other hand, 48.7% are estimated to tolerate eHF until the 24th month, and the total cost for the children tolerating eHF is estimated at 12.3 million€ and the average cost per child tolerating eHF until the 24th month is estimated at 1940€. Conclusion: The analysis revealed that the management of CMPA is associated with the economic burden on the healthcare system in Turkey. Treatment of CMPA with AAF seems to provide better clinical outcomes (high tolerability and less withdrawal due to taste or an allergic reaction) and to be an option with economic benefits when Turkey-specific conditions are considered.

1 March 2021 in Journal of Surgery and Medicine
Verified
Journal Article
Open access
PDF file
UDUğur Demi̇rsoy
Uğur Demi̇rsoy
FKFeza Kirbiyik
Feza Kirbiyik
ADAli Doğan
Ali Doğan
FCFunda Corapcioglu
Funda Corapcioglu
Background/Aim: Malnutrition is a dangerous comorbidity in children with cancer that can affect tolerance to treatment modalities such as chemotherapy and radiotherapy. It also adversely affects the treatment outcome and overall survival. It has been known that low Z score of body mass index (BMI) indicates malnutrition. This study aims to underline the effects of oral nutritional supplementation (ONS) on pediatric oncology patients. Methods: All records were collected from Kocaeli University Hospital, Department of Pediatric Oncology, Kocaeli, Turkey, and analyzed. Weight, height, and BMI status of sixty patients who received ONS with cancer treatment were recorded during visits up to 8 months after the start of ONS. Statistical analyses were maintained on the whole cohort as well as on following tumor sub-groups: CNS tumors (13.3%), lymphoma (18.3%), other tumors (68.3%). Results: Sixty malnourished pediatric oncology patients (64.6% male, 35.4% female) were included in the study cohort. BMI values of the majority (60%, P<0.05) of patients increased after ONS treatment while those of 40% decreased. BMI values also increased in the case of other tumors and lymphoma sub-groups (P<0.001 and P=0.012, respectively). Conclusion: This study underlined the benefits of ONS treatment in terms of BMI status among pediatric oncology patients. The recovery rate of nutritional status depends on malignancy, cancer type and location. '+st+' Bundy DA, de Silva N, Horton S, Patton GC, Schultz L, Jamison DT, et al. Investment in child and adolescent health and development: key messages from Disease Control Priorities. The Lancet. 2018;391(10121):687-99. Barr RD, Gomez-Almaguer D, Jaime-Perez JC, Ruiz-Argüelles GJ. Importance of nutrition in the treatment of leukemia in children and adolescents. Archives of Medical Research. 2016;47(8):585-92. Sala A, Pencharz P, Barr RD. Children, cancer, and nutrition—a dynamic triangle in review. Cancer. 2004;100(4):677-87. Brinksma A, Huizinga G, Sulkers E, Kamps W, Roodbol P, Tissing W. Malnutrition in childhood cancer patients: a review on its prevalence and possible causes. Critical reviews in oncology/hematology. 2012;83(2):249-75. Gonzalez MC, Pastore CA, Orlandi SP, Heymsfield SB. Obesity paradox in cancer: new insights provided by body composition. The American journal of clinical nutrition. 2014;99(5):999-1005. Pribnow AK, Ortiz R, Báez LF, Mendieta L, Luna‐Fineman S. Effects of malnutrition on treatment‐related morbidity and survival of children with cancer in Nicaragua. Pediatric Blood & Cancer. 2017;64(11):e26590. Ladas EJ, Arora B, Howard SC, Rogers PC, Mosby TT, Barr RD. A framework for adapted nutritional therapy for children with cancer in low‐and middle‐income countries: a report from the SIOP PODC Nutrition Working Group. Pediatric Blood & Cancer. 2016;63(8):1339-48. Sala A, Rossi E, Antillon F, Molina AL, de Maselli T, Bonilla M, et al. Nutritional status at diagnosis is related to clinical outcomes in children and adolescents with cancer: a perspective from Central America. European journal of cancer. 2012;48(2):243-52. Amoroso L. The second international conference on nutrition: implications for hidden hunger. Hidden Hunger. 115: Karger Publishers; 2016. p. 142-52. Demaio AR, Branca F. Decade of action on nutrition: our window to act on the double burden of malnutrition. BMJ global health. 2018;3(Suppl 1). Keys A, Fidanza F, Karvonen MJ, Kimura N, Taylor HL. Indices of relative weight and obesity. J Chronic Dis. 1972;25(6):329-43. Epub 1972/07/01. PubMed PMID: 4650929. Brinksma A, Huizinga G, Sulkers E, Kamps W, Roodbol P, Tissing W. Malnutrition in childhood cancer patients: a review on its prevalence and possible causes. Crit Rev Oncol Hematol. 2012;83(2):249-75. Epub 2012/01/24. doi: 10.1016/j.critrevonc.2011.12.003. PubMed PMID: 22264939. Hall DMB, Cole TJ. What use is the BMI? Archives of disease in childhood. 2006;91(4):283-6. doi: 10.1136/adc.2005.077339. PubMed PMID: 16551784. Ortega FB, Sui X, Lavie CJ, Blair SN. Body Mass Index, the Most Widely Used But Also Widely Criticized Index: Would a Criterion Standard Measure of Total Body Fat Be a Better Predictor of Cardiovascular Disease Mortality? Mayo Clinic proceedings. 2016;91(4):443-55. Epub 03/02. doi: 10.1016/j.mayocp.2016.01.008. PubMed PMID: 26948431. Lange BJ, Gerbing RB, Feusner J, Skolnik J, Sacks N, Smith FO, et al. Mortality in overweight and underweight children with acute myeloid leukemia. Jama. 2005;293(2):203-11. Brouwer C, Gietema J, Kamps W, De Vries E, Postma A. Changes in body composition after childhood cancer treatment: impact on future health status—a review. Critical reviews in oncology/hematology. 2007;63(1):32-46. Trimpe K, Shaw MR, Wilson M, Haberman MR. Review of the effectiveness of enteral feeding in Pediatric oncology patients. Journal of Pediatric Oncology Nursing. 2017;34(6):439-45. Esbenshade AJ, Simmons JH, Koyama T, Koehler E, Whitlock JA, Friedman DL. Body mass index and blood pressure changes over the course of treatment of pediatric acute lymphoblastic leukemia. Pediatric blood & cancer. 2011;56(3):372-8. Ogden CL, Kuczmarski RJ, Flegal KM, Mei Z, Guo S, Wei R, et al. Centers for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics version. Pediatrics. 2002;109(1):45-60. Nishimura N, Nakano K, Ueda K, Kodaira M, Yamada S, Mishima Y, et al. Prospective evaluation of incidence and severity of oral mucositis induced by conventional chemotherapy in solid tumors and malignant lymphomas. Supportive Care in Cancer. 2012;20(9):2053-9. Jones JA, Avritscher EB, Cooksley CD, Michelet M, Bekele BN, Elting LS. Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. Supportive care in cancer. 2006;14(6):505-15. Peterson D, Bensadoun R-J, Roila F,...

21 October 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
EMErgun METE
Ergun METE
BABuket Başa Akdoğan
Buket Başa Akdoğan
SUSÜLEYMAN UTKU UZUN
SÜLEYMAN UTKU UZUN
CZCemalettin Dost Zeyrek
Cemalettin Dost Zeyrek
FKFeza Kirbiyik
Feza Kirbiyik
AAAhmet AKCAY
Ahmet AKCAY
Background/Objectives: DNA methylation-based lymphocyte enumeration may provide an alternative to conventional immunophenotyping, but its associations with allergic phenotypes require careful interpretation. We examined these associations in a predominantly pediatric cohort. Methods: This retrospective study included 206 participants aged 1–57 years (189 aged <18 years; 57.8% male; median age 5 years, IQR 3–8), evaluated between 24 November 2025 and 28 February 2026. Absolute subset counts were derived from the epigenetic i.Mune TBNK assay and CBC lymphocyte counts. Group comparisons used Mann–Whitney U tests with Benjamini–Hochberg correction across 56 comparisons. Firth models adjusted for three subset counts, CD4/CD8 ratio, log(IgE+1), age, and sex; percentage-based, comorbidity-adjusted, and age-restricted sensitivity analyses were added. IgE-containing models included 201 complete cases. Results: Allergic rhinitis was associated with lower CD4+ counts in the primary model (OR per 100 cells/µL 0.923; p = 0.0009), with the association retained after comorbidity adjustment and age restriction but not in the percentage model. Atopic dermatitis was associated with log(IgE+1) (OR 1.475; p = 0.0009). Food allergy was associated with higher CD19+ counts in the primary model (OR per 100 cells/µL 1.060; p = 0.0341), but this association was not retained in sensitivity analyses. No absolute NK-count difference was found for food allergy. Single-marker discrimination was modest (CD4+ AUC for rhinitis 0.711). Conclusions: These exploratory associations are sensitive to the measurement scale and model specification. They do not establish phenotype-specific epigenetic mechanisms, standalone diagnostic utility, or functional immune monitoring.

31 July 2018 in Future Science OA
Verified
Journal Article
Open access
FÖFatih Özdener
Fatih Özdener
FKFeza Kirbiyik
Feza Kirbiyik
ADAli Evrim Dogan
Ali Evrim Dogan
Aim: To assess pediatric clinical nutrition research by analyzing clinical studies in the Middle East (ME) and globally. Methods: Using ClinicalTrials.gov, the numbers of clinical studies in the ME and globally were analyzed. Results: The majority of clinical nutrition trials are in North America and Europe. The ME accounts for 4% of all nutrition trials. The majority of pediatric nutrition studies in the ME are in the later phases or are observational and/or epidemiological studies with a focus on poor nutrition or nutrition disorders. Industry funding in the ME is mostly by regional or local companies; few major global companies are involved. Conclusion: The ME is not well represented in clinical nutrition studies involving children. Effort should be expended to rectify this. Lay abstract Nutritional disorders have become an important worldwide disease burden during the last several decades. The development of effective therapies for nutritional disorders requires clinical trials in the affected populations. Our results showed that although the Middle East currently has the highest proportion of children worldwide, it is not well represented in clinical trials on nutritional studies in children. Furthermore, there is suboptimal funding from the multinational nutrition industry. This analysis indicates that there is a reasonable rationale for inclusion of the Middle East in nutritional clinical research in children, and that there is an untapped opportunity for the expansion of clinical research in this region.